Rhode Island Chronicle

Chronic Myelomonocytic Leukaemia Pipeline Insight, Clinical Trials, and Emerging Drugs 2023 | Key Companies – Novartis, Humanigen, Incyte Corporation, Genentech, Celgene, and Others

 Breaking News
  • No posts were found

Chronic Myelomonocytic Leukaemia Pipeline Insight, Clinical Trials, and Emerging Drugs 2023 | Key Companies – Novartis, Humanigen, Incyte Corporation, Genentech, Celgene, and Others

May 23
05:26 2023
Chronic Myelomonocytic Leukaemia Pipeline Insight, Clinical Trials, and Emerging Drugs 2023 | Key Companies - Novartis, Humanigen, Incyte Corporation, Genentech, Celgene, and Others

DelveInsight’s, “Chronic Myelomonocytic Leukaemia Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 27+ pipeline drugs in the Chronic Myelomonocytic Leukaemia pipeline landscape. It covers the Chronic Myelomonocytic Leukaemia pipeline drug profiles, including Chronic Myelomonocytic Leukaemia clinical trials and nonclinical stage products. It also covers the Chronic Myelomonocytic Leukaemia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Recent Developmental Activities in the Chronic Myelomonocytic Leukaemia Treatment Landscape

 

  • In January 2023, Talquetamab is undergoing priority assessment at the FDA, and it might be approved for the treatment of relapsed/refractory myeloma as early as 2023. At ASH, LLS presented fresh information from their LLS National Patient Registry, which tracked the immune response to COVID-19 mRNA vaccinations in thousands of blood cancer patients.

 

  • In April 2023, Revumenib is presently being investigated in a phase 2 study with the intention of acquiring FDA approval for the treatment of persons with advanced AML who have these particular gene mutations, according to Dr. Stein. Additionally, he said, “we are currently conducting studies that examine combination therapies.” For instance, revumenib is currently being tested in combination with venetoclax (Venclexta), a different targeted medication that has showed promise in the treatment of AML.

 

Request a sample and discover the recent breakthroughs happening in the Chronic Myelomonocytic Leukaemia Pipeline landscape @ Chronic Myelomonocytic Leukaemia Pipeline Outlook

 

Chronic Myelomonocytic Leukaemia Overview

CMML is a form of leukaemia that is characterised by high numbers of white blood cells, called ‘monocytes’, in the blood and bone marrow. CMML is an uncommon blood cancer with features of two other types of blood cancer. Even though it has leukaemia as part of its name, the World Health Organisation (WHO) classifies CMML as a ‘mixed myelodysplastic (MDS) myeloproliferative neoplasm (MPN)’. MPN is a group of disorders of the bone marrow stem cells that produce excess numbers of one or more types of blood cells (red cells, white cells, or platelets).

 

Key Takeaways from the Chronic Myelomonocytic Leukaemia Pipeline Report

 

  • DelveInsight’s Chronic Myelomonocytic Leukaemia Pipeline report depicts a robust space with 25+ active players working to develop 27+ pipeline therapies for Chronic Myelomonocytic Leukaemia treatment.

 

  • The leading Chronic Myelomonocytic Leukaemia Companies include Novartis, Humanigen, Incyte Corporation, Genetech, Celgene, AbbVie, Amgen, Nerviano Medical Sciences, Guangzhou Lupeng Pharmaceutical, Stemline Therapeutics, Immune-Onc Therapeutics, Astex Pharmaceuticals, Kura Oncology, and others

 

  • Promising Chronic Myelomonocytic Leukaemia Pipeline Therapies include Glasdegib, Azacitidine, Guadecitabine, ON 01910.Na, rigosertib sodium, Decitabine, HYDROXYUREA, ASTX030 (cedazuridine + azacitidine), Cedazuridine, Fentanyl sublingual spray, Fragmin, and others

 

  • The Chronic Myelomonocytic Leukaemia companies and academics are working to assess challenges and seek opportunities that could influence Chronic Myelomonocytic Leukaemia R&D. The Chronic Myelomonocytic Leukaemia therapies under development are focused on novel approaches to treat/improve Diffuse Large B-Cell Lymphoma.

 

For further information, refer to the detailed Chronic Myelomonocytic Leukaemia Drugs Launch, Chronic Myelomonocytic Leukaemia Developmental Activities, and Chronic Myelomonocytic Leukaemia News, click here for Chronic Myelomonocytic Leukaemia Ongoing Clinical Trial Analysis

 

Chronic Myelomonocytic Leukaemia Emerging Drugs Profile

 

  • Sabatolimab: Novartis

Sabatolimab (MBG 453) is an anti T-cell immunoglobulin and mucin domain 3 (anti-TIM3) monoclonal antibody that is being developed by Novartis Oncology. The drug is currently in phase III stage of development for the treatment of Chronic Myelomonocytic Leukaemia.

 

  • Lenzilumab: Humanigen

Lenzilumab is a monoclonal antibody, which acts a granulocyte macrophage colony stimulating factor antagonists. Lenzilumab is well tolerated in patients with CMML, with no grade 3 or 4 treatment emergent adverse events or DLTs reported. The favorable safety and activity profile of lenzilumab warrants future evaluation as part of a combination regimen targeted to specific subtypes more likely to respond, including patients with NRAS mutations. The drug is currently in phase 2/3 stage of development for the treatment of CMML.

 

  • Ruxolitinib: Incyte Corporation

Jakafi is a first-in-class inhibitor of the JAK1 and JAK2 protein kinases and works by competitively inhibiting the ATP-binding catalytic site on JAK1 and JAK2. The result of this inhibition is disruption of cytokine and growth factor signaling pathways, leading to a decrease in proinflammatory cytokines and chemokines. In the clinical study, Ruxoltinib demonstrated meaningful clinical activity in CMML patients with splenomegaly and/or high disease symptom burden. The drug is already approved by the US Food and Drug Administration for the treatment of people with intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF, and post–essential thrombocythemia MF. Jakafi is also indicated for the treatment of people with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea. The drug is currently in Phase II stage of development for the treatment of Chronic Myelomonocytic Leukaemia.  

 

  • NMS-03592088: Nerviano Medical Sciences

NMS-03592088 (NMS-088) is a potent inhibitor of FLT3, KIT, and CSF1R kinases. NMS-088 is the most active compound among the FLT3 comparators, a finding especially evident in the presence of the FLT3 “gatekeeper mutation,” which is associated with clinical resistance to treatment with other FLT3 inhibitors. There is a rationale for the use of the molecule in Chronic Myelomonocytic Leukemia (CMML) on the basis of the demonstrated inhibition of CSF1R, a highly expressed and activated target in this tumor type. The drug is currently in the Phase I/II stage of development for the treatment of CMML.

 

  • LP-108: Guangzhou Lupeng Pharmaceutical

LP-108 is a proto-oncogene protein (c-bcl-2) inhibitor. The drug is currently in Phase I stage of development for the treatment of CMML.

 

Chronic Myelomonocytic Leukaemia Pipeline Therapeutics Assessment

There are approx. 25+ key companies which are developing the therapies for Diffuse Large B-Cell Lymphoma. The companies which have their Chronic Myelomonocytic Leukaemia drug candidates in the most advanced stage, i.e. phase III include, Novartis.

 

Find out more about the Chronic Myelomonocytic Leukaemia Pipeline Segmentation, Therapeutics Assessment, and Chronic Myelomonocytic Leukaemia Emerging Drugs @ Chronic Myelomonocytic Leukaemia Treatment Landscape

 

Scope of the Chronic Myelomonocytic Leukaemia Pipeline Report

 

  • Coverage- Global

 

  • Chronic Myelomonocytic Leukaemia Companies- Novartis, Humanigen, Incyte Corporation, Genetech, Celgene, AbbVie, Amgen, Nerviano Medical Sciences, Guangzhou Lupeng Pharmaceutical, Stemline Therapeutics, Immune-Onc Therapeutics, Astex Pharmaceuticals, Kura Oncology, and others

 

  • Chronic Myelomonocytic Leukaemia Pipeline Therapies- Glasdegib, Azacitidine, Guadecitabine, ON 01910.Na, rigosertib sodium, Decitabine, HYDROXYUREA, ASTX030 (cedazuridine + azacitidine), Cedazuridine, Fentanyl sublingual spray, Fragmin, and others.

 

  • Chronic Myelomonocytic Leukaemia Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for drugs for Chronic Myelomonocytic Leukaemia Pipeline Companies and Therapies, click here @ Chronic Myelomonocytic Leukaemia Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Chronic Myelomonocytic Leukaemia: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Chronic Myelomonocytic Leukaemia– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Sabatolimab : Novartis
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Ruxolitinib: Incyte Corporation
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. NMS-03592088: Nerviano Medical Sciences
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Chronic Myelomonocytic Leukaemia Key Companies
  21. Chronic Myelomonocytic Leukaemia Key Products
  22. Chronic Myelomonocytic Leukaemia – Unmet Needs
  23. Chronic Myelomonocytic Leukaemia – Market Drivers and Barriers
  24. Chronic Myelomonocytic Leukaemia – Future Perspectives and Conclusion
  25. Chronic Myelomonocytic Leukaemia Analyst Views
  26. Chronic Myelomonocytic Leukaemia Key Companies
  27. Appendix

 

Got Queries? Find out the related information on Chronic Myelomonocytic Leukaemia Mergers and acquisitions, Chronic Myelomonocytic Leukaemia Licensing Activities @ Chronic Myelomonocytic Leukaemia Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories